Hybio Pharmaceutical Co., Ltd.
300199
Rank in Stocks
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Share Price
$3.69
Market Cap
$3.11B
Change (1 day)
-7.75%
Change (1 year)
21.56%
Country
CN
Trade Hybio Pharmaceutical Co., Ltd. (300199)
Category
Healthcare
P/S ratio for Hybio Pharmaceutical Co., Ltd. (300199)
P/S ratio as of October 2026 TTM: 18.81
According to Hybio Pharmaceutical Co., Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 18.81. At the end of 2024 the company had a P/S ratio of 18.96.
P/S ratio history for Hybio Pharmaceutical Co., Ltd. from 2007 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 18.81 | 11.08% |
| 2025 | 16.93 | -10.70% |
| 2024 | 18.96 | -31.30% |
| 2023 | 27.60 | 25.21% |
| 2022 | 22.05 | 45.68% |
| 2021 | 15.13 | 85.95% |
| 2020 | 8.14 | -2.43% |
| 2019 | 8.34 | 29.72% |
| 2018 | 6.43 | -47.36% |
| 2017 | 12.21 | -34.34% |
| 2016 | 18.60 | -35.39% |
| 2015 | 28.79 | -0.94% |
| 2014 | 29.06 | 1.76% |
| 2013 | 28.56 | 126.22% |
| 2012 | 12.62 | -41.82% |
| 2011 | 21.70 | 19.62% |
| 2010 | 18.14 | -22.09% |
| 2009 | 23.29 | 5.26% |
| 2008 | 22.12 | -27.35% |
| 2007 | 30.45 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 2.82 | -85.03% |
DE
|
|
| 3.02 | -83.95% |
DE
|
|
| 2.19 | -88.37% |
JP
|
|
| 8.92 | -52.56% |
CH
|
|
| 7.04 | -62.56% |
IN
|
